Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911189 | 0.88 | AKR1C3 (0.49) | MAPTRAB9AKMT2ALMNASMN1; SMN2 | |
| SCHEMBL6041508 | 0.81 | ALDH1A1 (0.51) | MAPTKMT2ALMNASMN1; SMN2MEN1 | |
| SCHEMBL6042146 | 0.79 | PLA2G2A (0.45) | MAPTRAB9AKMT2ALMNASMN1; SMN2 | |
| SCHEMBL6044419 | 0.76 | CYSLTR1 (0.49) | MAPTRAB9ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL3846345 | 0.76 | L3MBTL1 (0.59) | MAPTRAB9ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL5522952 | 0.76 | PKM (0.53) | RAB9ASMN1; SMN2ALDH1A1L3MBTL1NPC1 | |
| SCHEMBL6041694 | 0.76 | MAPT (0.48) | MAPTRAB9ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL11842420 | 0.75 | KMT2A (0.66) | MAPTRAB9AKMT2ALMNASMN1; SMN2 | |
| SCHEMBL4912817 | 0.74 | TDP1 (0.52) | MAPTKMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL5647554 | 0.73 | L3MBTL1 (0.53) | MAPTKMT2ALMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786773-B1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RES TECH LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| EP-1786773-B1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RES TECH LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| US-8258175-B2 | Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-8258175-B2 | Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-8258175-B2 | Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786773-A1 | ISOINDOLIN-1-ONE DERIVATIVES | Cancer Research Technology Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024837-A1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024837-A1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261917-A1 | Isoindolin-1-One Derivatives | HCN3, NHERF1, SIGMAR1 | MAPT 4698/4885RAB9A 1376/4885KMT2A 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.